CD8A and neoplasm: So, the combination therapy of ipilimumab and nivolumab targeting both CD4 + PD-1lowTIM-3+ and CD8+ PD-1highTIM-3+ might be able to reverse the natural prognosis of RCC and be ideal for treating patients with higher tumour grade.